Cargando…

The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium

BACKGROUND: Pterygium is a proliferative disease with hyperplastic growth of corneoconjunctival fibro vascular tissue onto the cornea. Surgical therapy can be used to successfully manage pterygia; however, recurrence remains a problem. To reduce recurrence, surgical management may include autoconjun...

Descripción completa

Detalles Bibliográficos
Autores principales: Kareem, Alyaà Abood, Farhood, Qasim Kadhim, Alhammami, Hussein Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497463/
https://www.ncbi.nlm.nih.gov/pubmed/23152665
http://dx.doi.org/10.2147/OPTH.S38388
_version_ 1782249748431896576
author Kareem, Alyaà Abood
Farhood, Qasim Kadhim
Alhammami, Hussein Ali
author_facet Kareem, Alyaà Abood
Farhood, Qasim Kadhim
Alhammami, Hussein Ali
author_sort Kareem, Alyaà Abood
collection PubMed
description BACKGROUND: Pterygium is a proliferative disease with hyperplastic growth of corneoconjunctival fibro vascular tissue onto the cornea. Surgical therapy can be used to successfully manage pterygia; however, recurrence remains a problem. To reduce recurrence, surgical management may include autoconjunctival grafting, lamellar keratoplasty, amniotic membrane transplantation, and intraoperative antimetabolites application. PURPOSE: To assess the safety and the efficacy of intraoperative mitomycin C (MMC) and 5-fluorouracil (5-FU) application in preventing recurrence of pterygium after excision. PATIENTS AND METHODS: The study design is a prospective, randomized clinical trial. A total of 50 patients with bilateral pterygium were recruited for the study. The first group of patients (25) underwent surgical excision of the pterygium with bare sclera in one eye and MMC was applied as adjunctive therapy for the other eye. In the second group 5-FU was used instead of MMC. Recurrences and postoperative complications were measured in the two groups. The mean follow up period of the patients was 18.8 months. Chi square test, odds ratio, and frequency distribution were used to determine significance levels; P-values <0.05 were considered statistically significant. RESULTS: In group 1 the recurrence rate was 8% for the MMC treated eyes and 32% for their fellow eyes (P = 0.03). In group 2 the rate was 18% for the 5-FU treated eyes and 34% for their fellow eyes (P = 0.07). No serious complications were recorded in either group. CONCLUSION: Both MMC and 5-FU reduce the recurrence rate of pterygium after simple surgical excision; statistically, the effect of the former was significant, but insignificant for the latter. Both antimetabolites were safe during the whole study period, but 5-FU recurrent cases showed cosmetically unacceptable appearances with excessive vascularization. MMC, but not 5-FU, is recommended as an adjunctive therapy to prevent recurrence of pterygium after surgical excision.
format Online
Article
Text
id pubmed-3497463
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34974632012-11-14 The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium Kareem, Alyaà Abood Farhood, Qasim Kadhim Alhammami, Hussein Ali Clin Ophthalmol Original Research BACKGROUND: Pterygium is a proliferative disease with hyperplastic growth of corneoconjunctival fibro vascular tissue onto the cornea. Surgical therapy can be used to successfully manage pterygia; however, recurrence remains a problem. To reduce recurrence, surgical management may include autoconjunctival grafting, lamellar keratoplasty, amniotic membrane transplantation, and intraoperative antimetabolites application. PURPOSE: To assess the safety and the efficacy of intraoperative mitomycin C (MMC) and 5-fluorouracil (5-FU) application in preventing recurrence of pterygium after excision. PATIENTS AND METHODS: The study design is a prospective, randomized clinical trial. A total of 50 patients with bilateral pterygium were recruited for the study. The first group of patients (25) underwent surgical excision of the pterygium with bare sclera in one eye and MMC was applied as adjunctive therapy for the other eye. In the second group 5-FU was used instead of MMC. Recurrences and postoperative complications were measured in the two groups. The mean follow up period of the patients was 18.8 months. Chi square test, odds ratio, and frequency distribution were used to determine significance levels; P-values <0.05 were considered statistically significant. RESULTS: In group 1 the recurrence rate was 8% for the MMC treated eyes and 32% for their fellow eyes (P = 0.03). In group 2 the rate was 18% for the 5-FU treated eyes and 34% for their fellow eyes (P = 0.07). No serious complications were recorded in either group. CONCLUSION: Both MMC and 5-FU reduce the recurrence rate of pterygium after simple surgical excision; statistically, the effect of the former was significant, but insignificant for the latter. Both antimetabolites were safe during the whole study period, but 5-FU recurrent cases showed cosmetically unacceptable appearances with excessive vascularization. MMC, but not 5-FU, is recommended as an adjunctive therapy to prevent recurrence of pterygium after surgical excision. Dove Medical Press 2012 2012-11-08 /pmc/articles/PMC3497463/ /pubmed/23152665 http://dx.doi.org/10.2147/OPTH.S38388 Text en © 2012 Kareem et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Kareem, Alyaà Abood
Farhood, Qasim Kadhim
Alhammami, Hussein Ali
The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
title The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
title_full The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
title_fullStr The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
title_full_unstemmed The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
title_short The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
title_sort use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497463/
https://www.ncbi.nlm.nih.gov/pubmed/23152665
http://dx.doi.org/10.2147/OPTH.S38388
work_keys_str_mv AT kareemalyaaabood theuseofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium
AT farhoodqasimkadhim theuseofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium
AT alhammamihusseinali theuseofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium
AT kareemalyaaabood useofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium
AT farhoodqasimkadhim useofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium
AT alhammamihusseinali useofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium